Winton Group LTD Blueprint Medicines Corp Transaction History

Winton Group LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$54.1 - $110.08 $1.03 Million - $2.09 Million	-18,951 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$94.25 - $115.99 $1.03 Million - $1.27 Million	-10,951 Reduced 36.62%	18,951 $2.03 Million
Q3 2021 Oct 28, 2021	BUY	$80.98 - $109.47 $788,016 - $1.07 Million	9,731 Added 48.24%	29,902 $3.07 Million
Q2 2021 Aug 10, 2021	BUY	$82.78 - $101.0 $267,627 - $326,533	3,233 Added 19.09%	20,171 $1.77 Million
Q1 2021 Jul 21, 2021	BUY	$90.71 - $108.28 $154,479 - $184,400	1,703 Added 11.18%	16,938 $1.65 Million
Q4 2020 Feb 12, 2021	SELL	$92.08 - $124.48 $1.55 Million - $2.1 Million	-16,861 Reduced 52.53%	15,235 $1.71 Million
Q3 2020 Oct 30, 2020	BUY	$66.45 - $92.7 $2.13 Million - $2.98 Million	32,096 New	32,096 $2.98 Million
Q2 2019 Jul 08, 2019	SELL	$73.54 - $97.8 $226,282 - $300,930	-3,077 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$48.7 - $86.6 $149,849 - $266,468	3,077 New	3,077 $246,000
Q3 2018 Nov 02, 2018	SELL	$58.91 - $78.32 $186,744 - $248,274	-3,170 Closed	0 $0
Q2 2018 Aug 20, 2018	SELL	$60.96 - $101.18 $103,205 - $171,297	-1,693 Reduced 34.81%	3,170 $0
Q1 2018 May 21, 2018	BUY	$73.28 - $102.95 $356,360 - $500,645	4,863 New	4,863 $0

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.